Related Experiment Video
Updated: Jun 23, 2026
12:58
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
Plasmacytoid dendritic cell leukemia in children.
Asahito Hama1, Kazuko Kudo, Bustos Villalobos Itzel
1Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Journal of Pediatric Hematology/Oncology
|May 6, 2009
Summary
CD4/CD56 malignancies, rare cancers of plasmacytoid dendritic cells (pDC), present unique diagnostic challenges. Identifying specific cell markers aids in diagnosing this rare acute leukemia.
Area of Science:
- Hematologic Oncology
- Immunophenotyping
- Dendritic Cell Biology
Background:
- CD4/CD56 malignancies are rare hematologic neoplasms.
- These malignancies represent the malignant counterpart of plasmacytoid dendritic cells (pDC).
Observation:
- A 5-year-old boy presented with subcutaneous lesions and bone marrow blast cells.
- Initial diagnosis was acute unclassified leukemia, treated with AML chemotherapy.
- The patient relapsed with recurrent lesions and increased blast cells.
Findings:
- Immunophenotyping revealed blast cells positive for CD4, CD56, CD123, and blood dendritic cell antigen-2.
- These markers are characteristic of normal plasmacytoid dendritic cells (pDC).
- The specific CD4, CD56, CD3, CD13, CD19, CD33 profile is highly suggestive of pDC leukemia.
Implications:
- Accurate diagnosis of pDC-derived acute leukemia is crucial for appropriate treatment.
- CD123 and blood dendritic cell antigen-2 are valuable diagnostic markers for pDC leukemia.
- Understanding the immunophenotype aids in differentiating rare hematologic neoplasms.
